Swedish Orphan Biovitrum (OTCMKTS:BIOVF) Releases Earnings Results, Beats Expectations By $0.04 EPS

Swedish Orphan Biovitrum (OTCMKTS:BIOVF) released its earnings results on Thursday. The company reported $0.42 earnings per share for the quarter, beating analysts’ consensus estimates of $0.38 by $0.04, Zacks reports. Swedish Orphan Biovitrum had a return on equity of 16.66% and a net margin of 3.37%.

Swedish Orphan Biovitrum Price Performance

Shares of OTCMKTS BIOVF opened at $49.03 on Thursday. The company has a 50 day simple moving average of $47.89 and a 200 day simple moving average of $42.01. The company has a debt-to-equity ratio of 0.19, a current ratio of 0.70 and a quick ratio of 0.47. Swedish Orphan Biovitrum has a 1 year low of $28.93 and a 1 year high of $49.03. The firm has a market cap of $17.45 billion, a PE ratio of 163.43 and a beta of 0.35.

Wall Street Analysts Forecast Growth

Several equities research analysts recently weighed in on the stock. Pareto Securities cut shares of Swedish Orphan Biovitrum to a “hold” rating in a research report on Monday, June 29th. HC Wainwright began coverage on shares of Swedish Orphan Biovitrum in a research report on Wednesday, May 6th. They issued a “buy” rating for the company. Barclays reaffirmed an “overweight” rating on shares of Swedish Orphan Biovitrum in a report on Friday, July 3rd. Finally, Zacks Research raised shares of Swedish Orphan Biovitrum to a “hold” rating in a research note on Thursday, May 7th. Four analysts have rated the stock with a Buy rating and three have given a Hold rating to the company’s stock. Based on data from MarketBeat, Swedish Orphan Biovitrum has a consensus rating of “Moderate Buy”.

Swedish Orphan Biovitrum Company Profile

Swedish Orphan Biovitrum AB (publ), commonly known as Sobi, is a Stockholm‐based biopharmaceutical company specializing in the development, manufacturing and commercialization of treatments for rare diseases. Formed in 2010 through the merger of Swedish Orphan International AB (established 1985) and Biovitrum AB, the company focuses on high‐value therapies in hematology, immunology, oncology and genetic/metabolic disorders. Sobi’s strategy centers on building a global specialty care portfolio by in‐licensing, acquiring and internally developing innovative products aimed at small patient populations with significant unmet needs.

The company’s marketed portfolio includes recombinant clotting factor therapies such as Elocta (rFVIIIFc) and Alprolix (rFIXFc) for hemophilia A and B, respectively; Ruconest, a recombinant human C1 esterase inhibitor for hereditary angioedema; and Kineret (anakinra) for certain auto‐inflammatory conditions.